期刊
LABMEDICINE
卷 40, 期 5, 页码 297-302出版社
AMER SOC CLINICAL PATHOLOGY
DOI: 10.1309/LMOTQ5MUG76FMYMK
关键词
-
资金
- National Natural Foundation of China [30570786, 30770782]
- Guangdong Natural Science Foundation of China [8151008901000128]
- Program for New Century Excellent Talents in University [NCET-06-0721]
Objective: To investigate the apoptotic effects of peroxisome proliferator-activated receptor gamma (PPAR-gamma) agonist rosiglitazone (RGZ) on leukemia HL-60 cells. Methods: Cell apoptosis was measured by flow cytometry, Hoechst 33258 staining, and DNA fragmentation assay. The expression of caspase-3 and apoptosis-related gene Bax and Bcl-2 as well as survivin expression were analyzed by Western blotting. Results: Rosiglitazone (over 40 mu mol/L) could inhibit the growth of HL-60 cells and substantially cause apoptosis. Apoptotic cells were observed clearly by Hoechst staining, especially after the cells were treated with RGZ for 72 h, and a DNA fragmentation assay showed a typical DNA ladder. Western blotting showed cleavage of the caspase-3 zymogen protein (32-kD) with the appearance of its 17-kD cleavage and down-regulation of anti-apoptotic protein Bcl-2 and survivin as well as up-regulation of pro-apoptotic protein Bax. Conclusion: Rosiglitazone can inhibit HL-60 cell growth by the induction of apoptosis. Activation of caspase-3 and down-regulation of Bcl-2 and survivin as well as up-regulation of Bax expression may be one of its most important mechanisms.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据